Caribou Biosciences CRBU
NASDAQ CRBU
$0.39 -0.02 (-4.80%)
At close: Nov 11, 2026 · 4:00 PM EST

Caribou Biosciences (CRBU) Gains from Sales and Divestitures (2020 - 2026)

Updated

Analysis

Caribou Biosciences (CRBU) Gains from Sales and Divestitures (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Caribou Biosciences 44.30 Mn -419.78 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 254,000.00
Dec 31, 2024 13,000.00
Sep 30, 2024 -4,000.00
Mar 31, 2023 34,000.00
Dec 31, 2021 -1,000.00
Mar 31, 2021 -3,000.00
Sep 30, 2020 -70,000.00
API Access

Caribou Biosciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CRBU&period=max&api_key=YOUR_API_KEY